Danilo Giffoni M M Mata

6PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 24, 2026
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

|Jan 24, 2025
A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline-Taxane Chemotherapy in Early HER-2 Negative Breast Cancer.

Danilo Giffoni de Mello Morais Mata, Rossanna C Pezo, Kelvin K W Chan

|Aug 28, 2024
The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis.

Danilo Giffoni de Mello Morais Mata, Mary-Beth Rush, Megan Smith-Uffen

|Sep 09, 2023
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review.

Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B Hannouf

|Jul 28, 2023
Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.

Tian Xiao, Sanji Ali, Danilo Giffoni M M Mata

|Jul 25, 2022
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review.

Danilo Giffoni de Mello Morais Mata, Carlos Amir Carmona, Andrea Eisen

Pageof 1

Frequent Collaborators

3 joint publications

Maureen Trudeau

1 joint publications

Adam M Brufsky

1 joint publications

Reshma Mahtani

1 joint publications

Ahmed Elkhanany